Nature Communications (Aug 2021)
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
- Niels Grote Beverborg,
- Daniela Später,
- Ralph Knöll,
- Alejandro Hidalgo,
- Steve T. Yeh,
- Zaher Elbeck,
- Herman H. W. Silljé,
- Tim R. Eijgenraam,
- Humam Siga,
- Magdalena Zurek,
- Malin Palmér,
- Susanne Pehrsson,
- Tamsin Albery,
- Nils Bomer,
- Martijn F. Hoes,
- Cornelis J. Boogerd,
- Michael Frisk,
- Eva van Rooij,
- Sagar Damle,
- William E. Louch,
- Qing-Dong Wang,
- Regina Fritsche-Danielson,
- Kenneth R. Chien,
- Kenny M. Hansson,
- Adam E. Mullick,
- Rudolf A. de Boer,
- Peter van der Meer
Affiliations
- Niels Grote Beverborg
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Daniela Später
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Ralph Knöll
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Alejandro Hidalgo
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Steve T. Yeh
- Ionis Pharmaceuticals
- Zaher Elbeck
- Integrated Cardio Metabolic Center (ICMC), Karolinska Institutet
- Herman H. W. Silljé
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Tim R. Eijgenraam
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Humam Siga
- Integrated Cardio Metabolic Center (ICMC), Karolinska Institutet
- Magdalena Zurek
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Malin Palmér
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Susanne Pehrsson
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Tamsin Albery
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Nils Bomer
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Martijn F. Hoes
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Cornelis J. Boogerd
- Department of Molecular Cardiology, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht
- Michael Frisk
- Institute for Experimental Medical Research, Oslo University Hospital and KG Jebsen Center for Cardiac Research, University of Oslo
- Eva van Rooij
- Department of Molecular Cardiology, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), University Medical Center Utrecht
- Sagar Damle
- Ionis Pharmaceuticals
- William E. Louch
- Institute for Experimental Medical Research, Oslo University Hospital and KG Jebsen Center for Cardiac Research, University of Oslo
- Qing-Dong Wang
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Regina Fritsche-Danielson
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Kenneth R. Chien
- Integrated Cardio Metabolic Center (ICMC), Karolinska Institutet
- Kenny M. Hansson
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca
- Adam E. Mullick
- Ionis Pharmaceuticals
- Rudolf A. de Boer
- Department of Cardiology University Medical Center Groningen, University of Groningen
- Peter van der Meer
- Department of Cardiology University Medical Center Groningen, University of Groningen
- DOI
- https://doi.org/10.1038/s41467-021-25439-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Heart failure is a major cause of morbidity and mortality worldwide. Here the authors show that subcutaneous administration of antisense oligonucleotides targeting PLN is an effective strategy in preclinical models of genetic cardiomyopathy and ischemia-driven heart failure.
